Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. - Wikidata - awgldk - TriplyDB

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

http://www.wikidata.org/entity/Q38046743

about

Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease.Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.What is the need for comparative effectiveness studies in IBD?

P2860

Q26862821-44C136B0-A11F-4031-8955-263D2707843A Q34160082-31B58F7A-59C4-463C-BCCD-DC3A9DDCAA9B Q36689512-33C53ED9-D474-4FE6-8A76-7BD2E6B0DB3E Q38205873-11A124C6-E917-4A04-8253-B446695B4796 Q38248218-07A884BC-6A0C-4469-9FBF-791F1D01FD20 Q38344622-8A00A75F-93EE-4D10-9BD4-7C5F35AB2EEF Q38549995-C5B06854-C74D-48F9-B9E7-63AEB401B4D9 Q38750962-4222A508-270D-499E-8EB4-B9284B431066 Q39704305-B11E3353-DDEA-4968-AB02-6ED4D66E59EE Q40006169-7A23117E-DBCA-457C-AC9E-DEE22177F6BC Q50648388-E3EE7170-F2C9-42B9-B8CD-662CCA757E80

P2860

Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.

http://www.wikidata.org/entity/Q38046743

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Comparative effectiveness of a ...... ertiary referral IBD practice.

@en

type

label

Comparative effectiveness of a ...... ertiary referral IBD practice.

@en

prefLabel

Comparative effectiveness of a ...... ertiary referral IBD practice.

@en

P1433

Q38046743-A3EE1E91-EDAC-4F5B-8977-C5B9FC728D3F

P1476

Q38046743-CE66CE6F-7304-409A-9AE6-9ED505B715BF

P2093

Q38046743-08F1453F-4EC4-4995-95D9-DD2883CC930F

Q38046743-2675DAC0-9A90-4776-8D9B-9F566A0D1A13

Q38046743-4EE7E57F-836F-401F-85B1-C7CABC629AC6

Q38046743-68DD1A8B-4445-4686-8F0F-D2E9499424E2

P2860

Q38046743-1636E341-FE65-4479-8EEE-20EFA3F5DE9D

Q38046743-2E42D0F5-F2E7-4AE8-BBD2-3B742EA11FD0

Q38046743-3DAD3C57-94ED-4955-8F2D-2208487C9C5B

Q38046743-41F7A89A-EFAB-4913-92D6-4A944707EF98

Q38046743-45E99B1D-0A1B-4C0D-AD65-1ECC8049C68F

Q38046743-8EE89FA6-FDE4-422D-AB84-E5EB88CBCAF4

Q38046743-903D64B7-B17A-4DD0-B7ED-8CE4F58E308B

Q38046743-93A34B92-03AE-4918-911A-D6AFF8D1D6DE

Q38046743-A49CAAC3-AE19-4F79-8C24-2AA38D08CB0D

Q38046743-A57A4D08-0FB7-4DCF-96AB-6692D5A3CC01

P2888

Q38046743-17851231-7372-4C6E-BF38-4DEBABA1274B

P304

Q38046743-6C2D52E7-5C3E-41CA-AA74-FC566D5B64DB

P31

Q38046743-8D5C3D56-59B8-4CA7-840B-2F2BD6C63AE8

P356

Q38046743-944FD436-A321-41B7-A88C-2E74F0E33ED3

P433

Q38046743-117A3A62-7A95-4780-98F0-6982B9180284

P478

Q38046743-1422A066-7DF6-441C-8288-7CD2010A27AF

P577

Q38046743-472C14E1-076E-47D4-A704-AAEA9C1DD2BB

P6179

Q38046743-44838C77-9114-4FA3-924B-FA814D35C2BF

P698

Q38046743-525A617C-FF06-4B0E-B982-5DF7F338AC40

P921

Q38046743-227C0788-8A24-4F8A-93DB-7A5D9DA3AD11

Q38046743-943C3CA6-1A66-4C71-958D-7188BCD1135F

Q38046743-B3B2948F-384A-44F7-898A-E752E22F627B

P356

S10620-012-2323-0

P1433

Digestive Diseases and Sciences

P1476

Comparative effectiveness of a ...... ertiary referral IBD practice.

@en

P2093

Ankur Rustgi

http://www.w3.org/2001/XMLSchema#string

Patricia Langenberg

http://www.w3.org/2001/XMLSchema#string

Raymond K Cross

http://www.w3.org/2001/XMLSchema#string

Seema A Patil

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

Infliximab maintenance therapy for fistulizing Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Management of Crohn's disease in adults.

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.

P2888

s10620-012-2323-0

P304

209-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-012-2323-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023462941

http://www.w3.org/2001/XMLSchema#string

P698

23014844

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease